Acticor Biotech SAS (EPA:ALACT)

France flag France · Delayed Price · Currency is EUR
0.2500
0.00 (0.00%)
Inactive · Last trade price on Dec 9, 2024
-91.61%
Market Cap 3.92M
Revenue (ttm) n/a
Net Income (ttm) -16.47M
Shares Out 15.69M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,801
Average Volume 2,277
Open 0.2500
Previous Close 0.2500
Day's Range 0.2450 - 0.2500
52-Week Range 0.2200 - 5.3000
Beta -0.26
RSI 38.00
Earnings Date Mar 28, 2025

About Acticor Biotech SAS

Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It’s product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acut... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 31
Stock Exchange Euronext Paris
Ticker Symbol ALACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.